2021 Revenues ($USD) : $7,573,000,000
2021 R&D spend : $3,051,000,000
2021 Number of Employees : 3,900
Fiscal Year End : 12/31/2021
Leader : CEO Dr. Reshma Kewalramani

Headquartered in Boston's Innovation District, Vertex saw 22% revenue growth in 2021. Leading growth drivers include the cystic fibrosis triple-combination therapy Trikafta/Kaftrio, which includes elexacaftor, tezacaftor and ivacaftor. Another core member of its portfolio is Symdeko/Symkevi, a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator and CFTR corrector combo. The drug has a robust pipeline with candidates for cystic fibrosis, beta thalassemia, sickle cell disease, Type 1 diabetes, and chronic and acute pain. Its non-opioid painkiller candidate VX-548 recently achieved statistically significant and clinically meaningful results in two Phase 2 studies. —BB